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Abstract The objective of this study was to estimate the
probability of development of partial secondary treatment
failure (PSTF) in patients with cervical dystonia (CD) who
had been treated over up to 9 years with repetitive intra-
muscular injections of botulinum neurotoxin type A
(BoNT/A). The temporal course of treatment response in
patients in whom PSTF was detected retrospectively was
compared to patients with a normal clinical response. For
this purpose, charts of all CD patients treated in our out-
patient clinic between 1988 and 2001 were retrospectively
analyzed. Extracted data included time of all injections,
dose per visit, disease severity measured by TSUI scores,
and time of determination of neutralizing antibodies. Final
data analysis using a special formal definition of PSTF was
based on charts of 568 patients having exclusively been
treated with abobotulinumtoxinA. PSTF onset was
observed in our CD cohort during the entire treatment
period analyzed, with no clustering at any time point.
Probability to develop PSTF was 14.5 % in 9 years. Thus,
mean PSTF incidence was 1.6 % per year. The mean TSUI
score of patients with retrospectively defined PSTF
(n = 33) became already significantly worse after the
second injection when compared with the group without
PSTF (n = 535). Our data indicate that clinical response in
patients developing PSTF later on differs from that of
patients without PSTF already very early in the course of
botulinum neurotoxin type A treatment, and that PSTF
remains undetected at this early stage. Reduced response
may therefore be present in a number of CD patients who
think they still respond normally to continuous BoNT/A
treatment.
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Abbreviations
BoNT/A Botulinum neurotoxin type A
BoNT/B Botulinum neurotoxin type B
CD Cervical dystonia
MHDA Mouse hemidiaphragm assay
MLA Mouse lethality assay
NAB Neutralizing antibody
PSTF Partial secondary treatment failure
STF Secondary treatment failure
Introduction
Administration of botulinum neurotoxin type A (BoNT/A)
has proven safe and efficient in the treatment of cervical
dystonia (CD; Simpson et al. 2008) but intramuscular injec-
tions of the BoNT protein complex have to be performed
repeatedly to continuously suppress muscular hyperactivity
(Moore and Naumann 2003). This might result in the forma-
tion of neutralizing antibodies (NABs) and increases the risk
of secondary therapy failure (STF; Benecke 2012). High doses
and booster injections are risk factors for NAB development
and STF (Greene et al. 1994; Kessler et al. 1999).
Frequency estimates of NAB formation in CD patients
vary considerably from 1.2 % (Brin et al. 2008) using the
mouse lethality assay to 40 % (Kranz et al. 2008) including
patients with ‘‘borderline’’ antibody values in the mouse
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hemidiaphragm test, low antibody titers and continued
clinical responsiveness. Rates of full STF and partial STF
(PSTF) seem to lie in between these extremes and cluster
around 3–5 % (Zuber et al. 1993; Kessler et al. 1999;
Dressler and Hallett 2006; Mohammadi et al. 2009).
Nevertheless, several publications state that NABs can be
detected in only about 50 % of the patients developing STF
or PSTF (Kessler et al. 1999; Mohammadi et al. 2009;
Lange et al. 2009). Obviously, reported rates on STF or
NABs are rather confusing. To determine a reliable esti-
mate of incidence and prevalence of PSTF in a cohort of
long-term treated CD patients, the following study was
designed.
The first sign of STF development is usually a reduction
in efficacy duration reported by the patient (Dressler 2004).
The treating physician may react by performing clinical
screening tests (Kessler and Benecke 1997; Hanna et al.
1999; Birklein and Erbguth 2000; Nestor and Ablon 2011).
If these clinical tests support suspected PSTF, serum
samples may be screened or directly tested for antibodies
against the botulinum neurotoxin with ELISA or Western
blot assays (Moore and Naumann 2003; Hanna and Jan-
kovic 1998; Hanna et al. 1999), the mouse hemidiaphragm
assay (MHDA; Go¨schel et al. 1997) or the mouse lethality
assay (MLA; Hanna and Jankovic 1998). Therefore, PSTF
and/or NABs are only detected when patient and treating
physician realize that the current therapy has become
insufficient. This unsystematic approach implies that PSTF
and NABs remain undetected in a variety of patients
resulting in an underestimation of PSTF and/or NAB
prevalence.
By means of a more systematic approach, where a small
but representative sample of the patient cohort is clinically
tested and receives NAB analysis by means of the MHDA,
Kranz et al. (2008) estimated NAB prevalence in their CD
cohort as up to 40 % including patients with continued
responsiveness (see above). Because this method heavily
relies on the selection procedure for this small represen-
tative patient sample, it may overestimate PSFT or NAB
prevalence.
The exact method to estimate PSTF and NAB incidence
and prevalence is the Kaplan–Meier analysis of a system-
atically tested patient cohort. However, this method was
not used in recent studies (Brin et al. 2008; Comella et al.
2011; Naumann et al. 2013).
Some reports have suggested that STF occurs early in
the course of treatment (Duane et al. 1995; Dressler et al.
2000; Dressler 2004; Lange et al. 2009) with the implica-
tion that if PSTF does not occur during the first 2–3 years
of treatment it will unlikely occur during subsequent years.
This statement is, however, not based on systematic testing
of PSTF or NAB occurrence but on the above mentioned
clinical approach of testing for NAB presence only if
treatment failure becomes obvious. The suggestion that
STF develops only at an early treatment stage might have
caused patients and physicians to monitor the treatment
effects of BoNT injections more carefully at start of ther-
apy than after 8–10 successful injections.
We have therefore screened all charts of CD patients
having started BoNT treatment in our outpatient clinic
between 1988 and 2001 for the development of PSTF
during the course of BoNT therapy to precisely determine
PSTF incidence and prevalence in our cohort. We
hypothesize that the efficacy of BoNT injections is reduced
very early in the treatment of patients with subsequent
PSTF compared to patients who do not develop PSTF.
Patients and methods
Definition of partial secondary treatment failure
In our outpatient clinic, the TSUI score (Tsui et al. 1986) is
the standard tool for monitoring treatment efficacy in CD.
Patients usually receive BoNT/A injections every
10–14 weeks and the TSUI score is determined routinely
just before reinjection when the effect of the previous
injection is already decreasing or has ceased. Partial sec-
ondary treatment failure (PSTF) is assumed in a patient
when (1) he/she had previously had a good treatment
response (when the difference between the TSUI baseline
score determined at injection session 1 just before the first
injection and the TSUI score determined at injection session
number x (x C 2) is C3 points, and (2) a patient’s TSUI
score systematically worsens in spite of maintenance or
increase of dose starting at injection session number
y (y [ x) during BoNT/A treatment, and (3) the patient had
reported that the last two injections had been less effective
than the previous ones. A systematic worsening of the TSUI
score was defined as an increase in TSUI scores for more
than two points over two treatment cycles (=three consec-
utive TSUI scores). This definition of PSTF is based on at
least four TSUI scores being determined during treatment
with at least three consecutive BoNT/A injections.
Patients
A total of 1,438 charts of patients receiving treatment in our
botulinum toxin outpatient clinic between 1988 and 2001
were available; the 704 charts containing data of patients
with idiopathic CD were screened further by one of the
authors. Only patients exclusively treated with abobotuli-
numtoxinA (Dysport, Ipsen Ltd.) were included (n = 660).
Patients missing relevant demographic data (17 patients) or
who had been treated with onabotulinumtoxinA (Botox,
Allergan Inc.; 17 patients) or incobotulinumtoxinA
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(NT201 = Xeomin, Merz Pharmaceuticals; 10 patients)
were excluded. A further 92 patients were excluded who had
received only three BoNT/A injections to avoid a possible
placebo effect (ratings too positive after the first injection).
The remaining 568 charts of patients with at least four con-
secutive well-documented abobotulinumtoxinA injections
(=treatment over 1 year) were screened for the presence of
PSTF according to the definition presented above using the
TSUI scores in the charts. Total dose per visit, patient’s
report on efficacy of the preceding injection, and date of
collecting a serum sample for NAB assays were extracted
from the charts. According to the charts, antibody testing had
been performed if a patient had reported an insufficient
treatment effect and the treating physician suspected NAB
induction. Blood samples had been analyzed by means of the
mouse hemidiaphragm assay (MHDA; Go¨schel et al. 1997).
The entire cohort was divided into patients who developed
PSTF according to the retrospective classification (PSTF
subgroup) and patients who did not (NSTF subgroup).
Statistical analysis
The probability of continuous BoNT/A treatment without
development of PSTF was estimated using a Kaplan–Meier
analysis. The Kaplan–Meier approach takes into account
that duration of treatment is patient-dependent. Patient data
were censored from further analysis when therapy was
interrupted for at least one treatment cycle (implying that
the patient had not been treated for half a year). An
‘‘event’’ (=occurrence of PSTF) was defined to have
happened at the time when the TSUI score started to
worsen systematically (see arrows in Fig. 1). The Kaplan–
Meier analysis was not extended beyond 9 years
(108 months), because the number of patients (n = 230 at
108 months) rapidly decreased after 9 years. The straight-
forward reason is that BoNT treatment in our clinic was
started in 1988 and the number of patients being treated
rapidly increased during the first years.
TSUI scores of different injection time points were
compared non-parametrically by Wilcoxon rank sum test
between the PSTF and the NSTF subgroup. For the sake of
comparability and statistics, individual TSUI scores were
standardized (for each patient) as percentage of the corre-
sponding baseline TSUI score. Mean TSUI scores and
standard deviations were presented as percentages of mean
baseline scores (Fig. 3; mean baseline scores for the PSTF
and the NSTF group are given in Table 1).
Approval of the local ethics committee
Data collection was performed retrospectively in 2001 as
part of the doctoral thesis of one of the authors (Spiess
2005). We have a recent general approval of the local
ethics committee allowing us to take blood samples and
publish anonymized clinical data and results of antibody
testing of patients having given informed consent.
Results
Demographic characteristics and TSUI baseline scores of
the study population are summarized in Table 1. The
stratification according to development of PSTF shows
that baseline data were comparable between the PSTF and
the NSTF subgroups. One has to keep in mind that the
classification whether a patient belonged to the PSTF or
the NSTF subgroup was made many years ([11 years)
after the TSUI scores were determined. At the time of
treatment, the treating physician suspected PSTF (which
was clearly different from the definition of PSTF in the
present paper) only in 16 patients in whom NABs were















Fig. 1 Comparison of the course of BoNT treatment in three patients
with an initial TSUI score of 10. Patient 1 (open circle) showed
continuous improvement over seven treatment cycles. Due to
occupational reasons he ceased attending our clinic and his data
were censored in the Kaplan–Meier analysis after seven injections.
Patient 2 (dark circle) initially showed a good response which was
reduced after the second injection (indicated by the arrow on the left).
Patient 3 (gray circle) who had a better initial treatment response than
patients 1 and 2 developed partial secondary treatment failure after 38
treatment cycles (indicated by the arrow on the right)
Table 1 Baseline characteristics of the partial non-responders (PSTF
subgroup) and the remaining study population (NSTF subgroup)
Characteristic PSTF subgroup NSTF subgroup
Number of patients 33 535
Female 20 (60.6 %) 302 (56.4 %)
Male 13 (39.4 %) 233 (43.6 %)
Mean age at onset of CD (years) 48.8 ± 12.4 49.7 ± 12.6
Mean TSUI score 9.82 ± 2.01 9.88 ± 2.13
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According to our definition of PSTF, 33 patients (5.8 %)
were retrospectively defined as partial non-responders
between the years 1988 and 2001. Among those were 16
patients for whom the charts contained positive NAB titers
(16/568 = 2.8 %). Since we did not carry out systematic
antibody testing in all 33 PSTF patients, the percentage of
MHDA-positive patients within the PSTF group (48.5 %)
is probably underestimated.
Detection of PSTF
TSUI scores usually decrease after onset of BoNT therapy
and continuously improve with repetitive injections every
3 months as demonstrated for a single subject in Fig. 1
(open circle). This patient continuously improved while
being injected in our clinic seven times.
As mentioned in the introduction, a systematic short-
ening of efficacy duration usually provides a first hint for
the development of PSTF. In most cases, a reduction of
maximal efficacy at week 4 is observed later on in the
treatment (Dressler 2004). In our outpatient clinic, patients
are injected every 3 months, the duration of efficacy can
thus not be monitored directly. However, a systematic
worsening of CD severity corresponds to the reduction of
duration of efficacy as long as the duration of efficacy is
\3 months. Therefore, the charts of 568 CD patients were
screened for the presence of a systematic worsening of
TSUI scores over two treatment cycles. Two examples are
given in Fig. 1. In the first case (dark circle), PSTF
occurred very early in the course of BoNT/A treatment
9–12 months after an initial good treatment response. In
the other patient, PSTF developed after 38 injections (gray
circle).
Probability of continuous BoNT/A treatment
without development of PSTF
According to our definition of PSTF, a few of our patients
already developed PSTF early in the course of BoNT/A
treatment. However, there was no clear-cut clustering of
PSTF; onset of PSTF seemed to occur over the entire time
span analyzed (Fig. 2). The lower frequency of ‘‘events’’ in
later months merely reflects the decreasing number of CD
patients being continuously treated for a longer time.
The calculation of the Kaplan–Meier plot with censoring
of patients with interrupted or ceased treatment for what-
ever reason resulted in a much higher probability for the
occurrence of PSTF than the simple rate of patients with
PSTF (n = 33) as percentage (5.8 %) of all patients ana-
lyzed (n = 568). When the occurrence of PSTF at a certain
time point was weighted in relation to the number of
patients being continuously treated for the entire time span
up to that time point, a much higher PSTF probability
under continuous BoNT/A treatment was determined. This
probability is threefold higher and is 14.5 % over a time
span of 108 months. Thus the mean incidence of PSTF per
year was 1.61 (= 14.5/108 9 12) %. In contrast to the
hypothesis that PSTF mainly occurs early in the course of
treatment there was a clear tendency to an increase of PSTF
with duration of treatment (see regression parable in
Fig. 2).
Clinical evidence for early efficacy reduction
in patients subsequently developing PSTF
To compare the efficacy of BoNT/A treatment from the
very beginning between the NSTF and PSTF subgroup,
standardized TSUI scores were calculated for each patient
and each injection in both subgroups. The standardized
TSUI scores of the PSTF subgroup differed significantly
from the standardized TSUI scores of the NSTF subgroup
from the third visit onwards (see asterisk in Fig. 3) which
took place 3 months after the second injection just before
the third injection (Fig. 3). All 33 PSTF patients had an
initial good response (and thus were no primary non-
responders). The effect of the first injection (controlled at
visit 2) was exactly the same in the PSTF and the NSTF
subgroup (see Fig. 3).
Mean doses of abobotulinumtoxinA used in the treat-
ment of the PSTF subgroup (752 ± 32 U) were signifi-



















Fig. 2 Probability of continuous BoNT/A treatment without the
development of partial secondary treatment failure in patients with
cervical dystonia (Kaplan–Meier analysis). In case of treatment
interruption for at least one treatment cycle (implying that the patient
had not been treated for half a year), data were censored from further
analysis. An ‘‘event’’ (=occurrence of PSTF) was defined to have
occurred at the time when the TSUI score started to worsen
systematically (see arrows in Fig. 1). For sake of resolution only
probabilities between 0.5 and 1.0 are displayed (see ordinate scale)
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(703 ± 56 U; p \ 0.01)). In general, the doses used for
treatment of CD patients in our clinic between 1988 and
2001 were much higher than the doses used nowadays.
Discussion
Early reduction of efficacy in CD patients
with subsequent PSTF
Secondary treatment failure to BoNT injections was
observed soon after the introduction of BoNT/A in clinical
practice (Greene and Fahn 1992; Greene et al. 1994). There
is no doubt that BoNT/A resistance may occur very early in
the course of treatment even after only a few injections
(Dressler and Hallett 2006). This was not only observed in
CD treatment but also during therapy for bladder dys-
function (Schulte-Baukloh et al. 2007). Our comparison of
a subgroup of patients developing PSTF later on with
patients without PSTF showed significant differences in
treatment response already after the second BoNT/A
treatment and well before patients developed clinically
manifest partial/complete secondary treatment failure.
In contrast, clearly delayed onset of resistance to BoNT
therapy has also been reported (Tsui et al. 1986; Duane
et al. 1995; Dressler and Hallett 2006). Because the number
of patients being continuously treated long-term decreases
with time, the probability to detect patients with PSTF
necessarily also decreases with time. Though STF is
described to occur more likely during the first 2–3 years of
treatment (Dressler and Hallett 2006), our data demonstrate
that the occurrence of PSTF after 4 years is not rare. The
decrease of the Kaplan–Meier plot in Fig. 2 suggests that
the probability to be treated with BoNT without develop-
ment of PSTF declines in parallel with the number of
patients being treated for a certain time span or even faster.
In some patients, onset of PSTF was detected more than
5 years after onset of BoNT/A therapy. Nevertheless, long
before, patient and treating physician realized that a sec-
ondary treatment failure had developed, the clinical effect
already was significantly less pronounced than in patients
not developing PSTF. This is demonstrated in Fig. 3.
Therefore, the prevalence of factors leading to STF as for
example neutralizing antibodies is probably higher than
usually suspected. Whether this prevalence is as high as
40 % as reported by Kranz et al. (2008), has to be analyzed
in subsequent studies or falsified by adequate reanalysis of
already performed studies.
PSTF prevalence and incidence in long-term CD
treatment
At first glance, the PSTF prevalence rate of 5.8 % in our
CD cohort does not seem higher than the rates of secondary
non-responders in other larger CD study populations
(Zuber et al. 1993; Kessler et al. 1999; Dressler and Hallett
2006; Brin et al. 2008; Naumann et al. 2013). However, the
latter rates cannot be used to determine how many patients
will develop PSTF during continuous long-term BoNT
treatment, because continuity and duration of treatment
were not taken into account when calculating these rates.
Kaplan–Meier analysis is a more appropriate tool. Because
all patients who were not treated continuously are cen-
sored, the probability to ‘‘survive continuous BoNT treat-
ment without development of PSTF’’ must necessarily be
much higher. Therefore, the estimated rate of PSTF for our
CD patients is about threefold higher (14.5 % over a period
of 108 months [= 9 years]). The simple calculation of the
proportion of patients with PSTF (in a cohort) thus greatly
underestimates the incidence of PSTF and therewith the
prevalence of PSTF in patients being treated for a certain
time span.
This is also true for the treatment with onabotulinum-
toxinA. Regarding underestimation of incidence and
prevalence there is no difference between the different
BoNT/A preparations. However, the individual rates
reported in the literature for the different preparations are
different (for a review see Naumann et al. 2013).
A statistically more adequate method to estimate PSTF
and NAB prevalence was used by Kranz et al. (2008). They
randomly selected a small representative sample from their
























Fig. 3 Comparison of standardized mean TSUI scores (± SD) in the
PSTF subgroup (dark circle; n = 33) and the NSTF subgroup (open
circle; n = 535) from the first injection onwards. The first injection
had an equal effect in both subgroups. However, mean standardized
TSUI scores improved significantly more in the NSTF subgroup than
in the PSTF subgroup after the second BoNT/A injection (aster-
isk = p \ 0.05). The number of patients decreased with number of
injections (NSTF subgroup: baseline: N = 535; 5 inject.: N = 497;
10 inject.: N = 429; 15 inject.: N = 372; PSTF subgroup: baseline:
N = 33; 5 inject.: N = 32; 10 inject.: N = 30; 15 inject.: N = 29)
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and sweat test and showed a surprisingly high (up to 40 %)
PSTF and antibody rate (but they included patients with
‘‘borderline’’ antibody values in the mouse hemidiaphragm
test, low antibody titers and continued clinical respon-
siveness). This may reflect not only differences between
centers but might also relate to the reliability of their
procedure. Analysis of a second small sample would have
reduced the uncertainty of this approach considerably.
Furthermore, the sweat test might be more sensitive in
detecting PSTF than our method of subsequent scoring of
CD severity. In our opinion, the method used by Kranz
et al. (2008) is indeed adequate to estimate PSTF preva-
lence but heavily depends on an appropriate representative
sample selection.
Prevalence of neutralizing antibodies in long-term CD
treatment
Interestingly, not all patients with PSTF and STF develop
NABs. Greene et al. already reported in 1994 that some
patients who had improved after BoNT injections lost
efficacy without serological evidence of antibodies. In
another study, the secondary non-responder rate was 5 %
but only 2 % of 303 CD patients had NABs (Kessler et al.
1999). Voller et al. (2004) reported 18 patients with sec-
ondary non-response but only 9 of them had positive NAB
titers, and Cordivari et al. (2006) found that not all of the
11 reported patients with poor response to EMG-guided
injections had positive antibody titers. In a larger series of
blood samples of secondary non-responders (being sent to a
central lab) only 44.5 % of the samples were MHDA-
positive (Lange et al. 2009). These observations and
numbers concur with our data of 16 patients with NABs
(= 45.8 %) among 33 PSTF patients. However, according
to our Kaplan–Meier PSTF analysis, this implies that NAB
prevalence in our CD patients who were continuously
treated for 9 years will be at least 6.6 %. Thus, Greene
et al. (1994) were correctly guessing that the actual prev-
alence of serologically detectable antibodies may be higher
than 4 %, and the data reported by Kranz et al. (2008)
indicate a much higher, probably too high NAB
prevalence.
Implications of high prevalence and early detection
of PSTF in long-term CD treatment
Usually (complete) secondary treatment failure is assumed
to be present when patient and treating physician do not see
a clinical response. However, as pointed out by Dressler
(2004), the lack of response does not occur suddenly from
one treatment to the next but develops over several treat-
ment cycles starting with a reduction in duration of clinical
effect and ending with an additional significant reduction
of maximal effect at weeks 2–4. A careful analysis of the
clinical effect every 12 weeks (as performed in the present
study) is a sensitive tool to detect the systematic reduction
of the duration of the clinical effect by documenting a
systematic worsening of subsequent TSUI scores. Thus, by
means of our definition of PSTF onset of PSTF can be
detected early, long before complete secondary therapy
failure is observed. Keeping the duration of treatment
cycles constant may thus be helpful in detecting PSTF
early.
The steepness of a Kaplan–Meier curve very much
depends on the definition of PSTF and the sensitivity of
measurement. PSTF was detected in some of our patients
only by retrospective analysis of their charts but not in
clinical routine which indicates that the detection sensi-
tivity may be lower in daily practice as compared to a
rigorous retrospective analysis. These considerations imply
that it will be difficult to detect PSTF onset in a practice
setting where injections are given by different physicians.
When patients are scored carefully and the scores are
available for each injection session there might be a chance
to detect PSTF early.
In summary, evidence is presented here that reduction of
efficacy may occur early in the course of BoNT/A treat-
ment in CD patients developing clinical manifest PSTF
years later. Careful monitoring and scoring of treatment
effect in CD is therefore recommended to detect PSTF
early and to avoid the development of complete therapy
failure and the induction of high titers of neutralizing
antibodies.
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